Drug-induced lymphopenia: Are all fumarates the same?

Mult Scler

Department of Neurology, St. Josef-Hospital, Ruhr-University Bochum, Bochum, Germany.

Published: September 2024


Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Download full-text PDF

Source
http://dx.doi.org/10.1177/13524585241242011DOI Listing

Publication Analysis

Top Keywords

drug-induced lymphopenia
4
lymphopenia fumarates
4
fumarates same?
4
drug-induced
1
fumarates
1
same?
1

Similar Publications

Background: Solid organ transplantation is hindered by immune-mediated chronic graft dysfunction and the side effects of immunosuppressive therapy. Regulatory T cells (Tregs) are crucial for modulating immune responses post-transplantation; however, the transfer of polyspecific Tregs alone is insufficient to induce allotolerance in rodent models.

Methods: To enhance the efficacy of adoptive Treg therapy, we investigated different immune interventions in the recipients.

View Article and Find Full Text PDF

Objective: To describe leflunomide as an adjunctive therapy in the treatment of non-associative immune-mediated thrombocytopenia.

Materials And Methods: A retrospective study of dogs with a diagnosis of non-associative immune-mediated thrombocytopenia treated with leflunomide March 2008 to September 2021 was conducted. Data collected included signalment, clinical signs, physical examination findings and diagnostic testing performed.

View Article and Find Full Text PDF

Progressive multifocal leukoencephalopathy (PML) is a severe demyelinating disease of the central nervous system (CNS) caused by reactivation of the polyomavirus JC (JCV) typically in immunocompromised individuals. The risk of PML among rheumatic diseases may be higher for systemic lupus erythematosus (SLE), without, however, a clear association with the type and intensity of background therapy. We present the development and outcome of PML in a 32-year-old female lupus patient under mild immunosuppressive treatment, yet with marked B-cell lymphopenia in the peripheral blood and bone marrow (<1% of total lymphocytes).

View Article and Find Full Text PDF

Secukinumab-induced systemic lupus erythematosus in psoriatic arthritis.

ARP Rheumatol

November 2023

Rheumatology and Metabolic Bone Diseases Department, Hospital de Santa Maria, Centro Hospitalar Universitário Lisboa Norte, Lisbon Academic Medical Center, European Reference Network on Rare Connective Tissue and Musculoskeletal Diseases Network.

Case Report: A 68-year-old male treated with secukinumab for psoriatic arthritis suspended treatment for three months due to COVID pandemic. Upon secukinumab reintroduction, anorexia and weight loss ensued and four months later he had an abrupt onset of low-grade fever, fatigue, flu-like symptoms, dyspnoea and widespread inflammatory arthralgias. Laboratory investigations showed de novo anaemia, leukopenia, lymphopenia, cytocholestasis, elevated acute phase reactants, C3 complement consumption, proteinuria (1630mg/24h), active urine sediment, positive antinuclear (1:1280) and anti-double-stranded DNA (212.

View Article and Find Full Text PDF